Publications

Article

Current IssueArchivesAbout UsAdvertising SubscribeReprints and PermissionsContact UsGuide to AuthorsEditors and Publishers
 

 

Recent Videos
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
2 experts in this video
2 experts in this video
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Related Content
63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q

63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q

Sheng Chow;Meredith Shamamian;Susan Laura Jao;Andreina Giron;Jessica Lin;Fardeen Bhimani;Eleni Kohilakis;Caroline Oska;Jana Fox;Sheldon Feldman;Maureen McEvoy
May 14th 2025
Article
Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Among 18 patients with central nervous system lymphoma treated with the ibrutinib/ nivolumab combination regimen, 3 were in remission beyond 2 years.

Ibrutinib/Nivolumab Shows Clinical Activity in R/R CNS Lymphoma

Roman Fabbricatore
May 14th 2025
Article

Among 18 patients with central nervous system lymphoma treated with the ibrutinib/ nivolumab combination regimen, 3 were in remission beyond 2 years.

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

The safety profile of loncastuximab tesirine plus glofitamab was consistent with the known profiles of the individual agents.

Loncastuximab Tesirine Combo Demonstrates Early Efficacy in R/R DLBCL

Roman Fabbricatore
May 14th 2025
Article

The safety profile of loncastuximab tesirine plus glofitamab was consistent with the known profiles of the individual agents.

Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System

Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System

Nathalie Soler, MD;Kelly Paz Amador, MD;Alexandra Perez, MD;Camila Solis, MD;Alexander Reyes, MD;Jorge Garcia, MD;Maria Paula Gonzalez Zambrano, MD;Edgar Fabián Manrique Hernández, MD, MSc, PhD (c)
May 14th 2025
Article

Anaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.